Dr. Boas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
191 Waukegan Rd Ste 200
Northfield, IL 60093Phone+1 847-998-3434Fax+1 847-998-8584
Summary
- Specializing in Sports Pulmonology
Education & Training
- UPMC Medical EducationFellowship, Pediatric Pulmonology, 1992 - 1995
- Nassau University Medical CenterResidency, Pediatrics, 1990 - 1992
- Boston Children’s Hospital/Boston Medical CenterInternship, Pediatrics, 1989 - 1990
- Stony Brook University Health Sciences Center School of MedicineClass of 1989
Certifications & Licensure
- IL State Medical License 1995 - 2026
- IN State Medical License 2005 - 2025
- PA State Medical License 1992 - 1996
- NY State Medical License 1992 - 1992
- American Board of Pediatrics Pediatric Pulmonology
- National Board of Physicians and Surgeons Pediatrics
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
- Fellow (FAAP) American Academy of Pediatrics
Publications & Presentations
PubMed
- 95 citationsCardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis.Helge Hebestreit, Erik H. J. Hulzebos, Jane E. Schneiderman, C. Karila, Steven R. Boas
American Journal of Respiratory and Critical Care Medicine. 2019-04-15 - Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis.Helge Hebestreit, Erik H J Hulzebos, Jane E Schneiderman, Chantal Karila, Steven R Boas
American journal of respiratory and critical care medicine. 2018-10-16 - 27 citationsCFTR genotype and maximal exercise capacity in cystic fibrosis a cross-sectional studyThomas Radtke, Helge Hebestreit, Sabina Gallati, Jane E. Schneiderman, Julia Braun
Annals of the American Thoracic Society. 2017-11-15
Press Mentions
- 1st CF Patient Screened for Phase 2 Trial of Adrulipase to Treat EPIFebruary 7th, 2023
- First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic FibrosisFebruary 2nd, 2023
- First Sites Selected for Enhanced Adrulipase Formulation Phase 2 TrialDecember 8th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: